GURU.Markets stock price, segment price, and overall market index valuation
The company's share price SpringWorks Therapeutics
SpringWorks is a biopharmaceutical company focused on rare cancers and tumors. Its stock price reflects both revenue from its approved drug and the success of other developments in its pipeline.
Share prices of companies in the market segment - Oncology targeted therapy
SpringWorks Therapeutics is an oncology company focused on developing targeted therapies for rare tumors and hematological cancers. We've categorized it as a "Targeted Oncology" company. The chart below shows how the market values companies working in the field of orphan oncology.
Broad Market Index - GURU.Markets
SpringWorks Therapeutics is an oncology company focused on developing targeted therapies for rare tumors and hematological cancers. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how SpringWorks shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
SWTX - Daily change in the company's share price SpringWorks Therapeutics
SpringWorks Therapeutics' daily share price fluctuations reflect the high volatility inherent in biotech companies. This metric measures the company's sensitivity to sales of its oncology drugs and new research data.
Daily change in the price of a set of shares in a market segment - Oncology targeted therapy
SpringWorks Therapeutics is a biopharmaceutical company specializing in the development of targeted therapies for the treatment of rare tumors and cancer. Oncology is a volatile sector. The chart below reflects the average fluctuations in this industry, providing context for evaluating SWTX stock.
Daily change in the price of a broad market stock, index - GURU.Markets
SpringWorks Therapeutics is a biotech company specializing in the development of targeted therapies for cancer treatment. Its shares are buoyed by anticipation of clinical trial results. These sharp movements are part of a complex mosaic of stock market volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization SpringWorks Therapeutics
For SpringWorks Therapeutics, the year-over-year performance is a story of transitioning to commercialization. Its market cap growth over the past 12 months reflects the successful approval and launch of its first drug for the treatment of desmoid tumors. Its valuation reflects the belief that its approach to developing targeted therapies for rare cancers will prove successful.
Annual dynamics of market capitalization of the market segment - Oncology targeted therapy
SpringWorks, a late-stage biotech company, develops drugs to treat rare cancers. Its stock performance is entirely dependent on clinical trial results and commercial success. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
SpringWorks Therapeutics is a biotech whose value is locked into its cancer drug pipeline. Its shares move in sync with clinical trial news. A sharp rise or fall amid a calm market is clear evidence that investors are betting on science.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization SpringWorks Therapeutics
SpringWorks is a commercial-stage oncology company. Its monthly performance reflects both sales growth of its approved targeted therapies and progress in its clinical pipeline. Quarterly revenue reports and trial data are the primary drivers.
Monthly dynamics of market capitalization of the market segment - Oncology targeted therapy
SpringWorks Therapeutics is a biopharmaceutical company specializing in the development of targeted therapies for the treatment of rare tumors and hematological cancers. The chart below shows the overall dynamics of the biotech sector, where precision oncology is a key focus.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
SpringWorks Therapeutics is a biotech company specializing in drugs for the treatment of rare cancers. Its stock price doesn't follow the market, but rather depends on the results of clinical trials and the commercial success of its products. Its performance is driven by innovation in oncology.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization SpringWorks Therapeutics
Oncology company SpringWorks shares reflect progress in targeted therapy every week. Their price movements reflect data from clinical trials of their drugs for rare cancers, where precise tumor targeting is crucial.
Weekly dynamics of market capitalization of the market segment - Oncology targeted therapy
SpringWorks Therapeutics specializes in developing precision oncology drugs for rare cancers. This chart helps separate its own news-driven dynamics from the overall fluctuations in the oncology sector, highlighting its place in this high-risk but potentially lucrative niche.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
SpringWorks Therapeutics is a biotech company. Its shares can be highly volatile and sensitive to research news. This chart will help you understand whether SpringWorks is living in its own world of clinical trials, or whether the overall market environment and risk appetite in biotech are influencing its stock price.
Market capitalization of the company, segment and market as a whole
SWTX - Market capitalization of the company SpringWorks Therapeutics
SpringWorks' market capitalization tells the story of a successful biotech company specializing in developing targeted therapies for rare cancers. Its steady growth chart reflects the successful approval and launch of its first drug. Its dynamics reflect the market's assessment of both current sales and the potential for future developments.
SWTX - Share of the company's market capitalization SpringWorks Therapeutics within the market segment - Oncology targeted therapy
SpringWorks Therapeutics specializes in developing targeted therapies for rare cancers. Its share of its biotech segment's market capitalization reflects the valuation of its promising drugs. The chart shows how its share changes as drugs progress through clinical trials.
Market capitalization of the market segment - Oncology targeted therapy
SpringWorks Therapeutics is a biopharmaceutical company specializing in the development of targeted therapies for rare cancers. The chart below shows the market capitalization of the oncology sector. Its dynamics provide the backdrop against which SpringWorks is attempting to bring its innovative drugs to market.
Market capitalization of all companies included in a broad market index - GURU.Markets
SpringWorks Therapeutics is a biotech company specializing in the development of targeted therapies for rare cancers. Its market cap represents hope for patients and investor confidence in precision oncology. Its momentum reflects how science is learning to attack cancer at the molecular level.
Book value capitalization of the company, segment and market as a whole
SWTX - Book value capitalization of the company SpringWorks Therapeutics
SpringWorks' book value is its capital, which is dedicated to the development and commercialization of targeted therapies for rare cancers and tumors. This is a tangible, scientific foundation built on a partnership with Pfizer. How has this successful biotech asset grown? The chart below shows its dynamics.
SWTX - Share of the company's book capitalization SpringWorks Therapeutics within the market segment - Oncology targeted therapy
SpringWorks Therapeutics develops targeted therapies for the treatment of rare tumors and cancer. The chart shows the share of its R&D assets, reflecting the physical foundation on which the company conducts its clinical trials.
Market segment balance sheet capitalization - Oncology targeted therapy
SpringWorks, a biopharmaceutical company, has a relatively lightweight model. It focuses on drug development, often outsourcing manufacturing. The BCap_Seg chart for the biotech sector serves as a backdrop, showing varying levels of capital intensity.
Book value of all companies included in the broad market index - GURU.Markets
SpringWorks' balance sheet isn't its factories, but its portfolio of targeted drugs for treating rare cancers and tumors. The company's assets are its intellectual property and clinical trial data. The chart below shows how this rare cancer-focused biotech company breaks down its assets.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - SpringWorks Therapeutics
SpringWorks Therapeutics specializes in rare oncological diseases. Its balance sheet represents the value of its pipeline of drug candidates. Its market capitalization reflects investors' high valuation of the potential of its targeted therapies. The chart reflects hopes for creating new standards of treatment in oncology.
Market to book capitalization ratio in a market segment - Oncology targeted therapy
SpringWorks Therapeutics specializes in developing targeted therapies for rare cancers and tumors, often in partnership with major pharmaceutical companies. Its high score on the chart reflects the potential of its precision scientific approach to oncology.
Market to book capitalization ratio for the market as a whole
SpringWorks Therapeutics is a biopharmaceutical company focused on rare diseases and cancer. Its market valuation reflects investor confidence in the potential of its drug candidates. The chart shows how high the biotech innovation premium is compared to the average market valuation.
Debts of the company, segment and market as a whole
SWTX - Company debts SpringWorks Therapeutics
SpringWorks Therapeutics, an oncology company specializing in rare tumors, is using the capital to commercialize its first approved drug and advance other clinical programs. This chart shows how the company is funding its transition from R&D to a fully commercial biopharmaceutical company.
Market segment debts - Oncology targeted therapy
SpringWorks Therapeutics is a commercial biopharmaceutical company specializing in rare tumors and cancers. This chart shows how the company manages its finances during the commercialization phase of its first product, balancing sales revenue with high R&D costs for the rest of its portfolio.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio SpringWorks Therapeutics
SpringWorks Therapeutics is a biotech company specializing in drugs for the treatment of rare oncological diseases. Developing such drugs requires significant investment. This chart shows the company's reliance on debt to fund its clinical trials, a key indicator of its financial risk.
Market segment debt to market segment book capitalization - Oncology targeted therapy
SpringWorks Therapeutics specializes in developing drugs to treat rare cancers and tumors. This area requires deep scientific expertise and significant investment. The chart shows how aggressively the biotech sector uses debt, providing context for assessing how SpringWorks finances its niche oncology programs.
Debt to book value of all companies in the market
SpringWorks Therapeutics, a biopharmaceutical company focused on rare cancers, requires significant investment to advance its drugs through clinical trials. This chart, showing the overall market debt burden, provides context. It helps assess how the company's financial strategy aligns with the high risks of the targeted oncology sector.
P/E of the company, segment and market as a whole
P/E - SpringWorks Therapeutics
SpringWorks Therapeutics is a biopharmaceutical company focused on developing targeted therapies for the treatment of rare tumors and hematological malignancies. This chart shows how investors value its pipeline. The valuation is based on clinical trial success and commercial potential.
P/E of the market segment - Oncology targeted therapy
This industry metric represents the average P/E for biotech companies. For SpringWorks Therapeutics, which focuses on rare tumors, it serves as a benchmark. It reflects the overall level of investor confidence in oncology, providing context for SpringWorks' valuation, which is betting on the success of its targeted drugs.
P/E of the market as a whole
SpringWorks Therapeutics is a biopharmaceutical company specializing in developing drugs to treat rare cancers and other diseases. Its valuation depends entirely on the success of its drugs in clinical trials and regulatory approval. Overall market sentiment, as reflected in this chart, is completely irrelevant to the company.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company SpringWorks Therapeutics
This chart for SpringWorks Therapeutics, a biopharmaceutical company focused on rare tumors and cancers, shows market expectations for its drugs. It reflects sales forecasts for the approved drug and the success of other clinical programs.
%20P%2FE%20SpringWorks%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-SpringWorks-Therapeutics&v=1772513457058 "Chart of the company's future (projected) P/E SpringWorks Therapeutics")
Future (projected) P/E of the market segment - Oncology targeted therapy
SpringWorks Therapeutics is a biopharmaceutical company specializing in the development of precision oncology drugs for the treatment of rare tumors and cancers with specific genetic mutations. This chart shows forecasts for the oncology sector. This helps assess the market perception of SpringWorks' targeted drug portfolio and its commercial prospects.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-targeted-therapy&v=1772513457069 "Future (projected) P/E graph of the market segment - Oncology targeted therapy")
Future (projected) P/E of the market as a whole
SpringWorks Therapeutics, Inc. is a biopharmaceutical company specializing in the development of targeted therapies for rare cancers. Its model is to discover and develop promising drugs. This chart of overall risk appetite shows how willing investors are to support companies working in niche but important areas of oncology.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513457087 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit SpringWorks Therapeutics
SpringWorks Therapeutics is an oncology company specializing in developing drugs for rare tumors and genetically defined cancers. The company already has a commercial product. This graph shows the transition from an unprofitable R&D stage to profitability through the successful commercialization of a niche oncology drug.
Profit of companies in the market segment - Oncology targeted therapy
SpringWorks Therapeutics is a biopharmaceutical company focused on developing targeted therapies for rare cancers and tumors. This chart, reflecting profitability in the oncology sector, demonstrates the importance of finding solutions for patients with limited treatment options. Their model is based on licensing and developing promising drugs from major pharmaceutical companies.
Overall market profit
SpringWorks Therapeutics is a biopharmaceutical company specializing in the development of targeted therapies for rare cancers and tumors. Its business model is based on licensing promising developments from large companies. Success depends on clinical trial results. This gross profit chart reflects the investment climate important for funding such projects.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company SpringWorks Therapeutics
SpringWorks Therapeutics specializes in developing targeted therapies for rare cancers and genetically defined tumors. This chart summarizes analyst opinions on the clinical prospects and commercial potential of their drugs, which are aimed at patients with limited treatment options.
%20profit%20of%20the%20company%20SpringWorks%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-SpringWorks-Therapeutics&v=1772513457143 "Graph of future (projected) profit of the company SpringWorks Therapeutics")
Future (predicted) profit of companies in the market segment - Oncology targeted therapy
SpringWorks Therapeutics is a biopharmaceutical company specializing in the development of targeted therapies for rare cancers and tumors. Its model is based on the acquisition and development of promising assets. This chart for the oncology sector reflects the overall investor interest in innovative treatments and the growth potential for companies operating in this field.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-targeted-therapy&v=1772513457188 "Graph of future (predicted) profits of companies in a market segment - Oncology targeted therapy")
Future (predicted) profit of the market as a whole
SpringWorks Therapeutics is a biopharmaceutical company specializing in rare diseases and cancer. Its value is determined by the potential of its drugs. The overall economic sentiment reflected in this forecast influences the valuation of the entire biotech industry and investors' risk appetite.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513457194 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - SpringWorks Therapeutics
SpringWorks Therapeutics is a biopharmaceutical company specializing in the development of targeted therapies for the treatment of rare cancers and tumors. The chart shows how investors estimate the revenue from its first commercial product. It reflects its ability to successfully bring drugs to market for niche but important patient groups.
P/S market segment - Oncology targeted therapy
SpringWorks Therapeutics specializes in developing targeted therapies for rare cancers and serious diseases. The company's valuation is based on the future potential of its clinical programs. This chart, which displays the average valuation in oncology, provides context for understanding how the market values SpringWorks' development pipeline and scientific approach.
P/S of the market as a whole
SpringWorks Therapeutics is a biopharmaceutical company focused on developing targeted therapies for rare cancers and tumors with specific genetic mutations. This chart, which reflects revenue estimates for real businesses, highlights that SpringWorks' value stems from investors' faith in its scientific approach and potential to help patients.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company SpringWorks Therapeutics
SpringWorks Therapeutics is a biotechnology company specializing in the development of targeted therapies for rare cancers and tumors. Its model is to partner with major pharmaceutical companies to develop promising molecules. This chart reflects investor expectations regarding the success of its clinical programs and the future commercial potential of its drugs.
%20P%2FS%20SpringWorks%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-SpringWorks-Therapeutics&v=1772513457376 "The graph of the company's future (projected) P/S SpringWorks Therapeutics")
Future (projected) P/S of the market segment - Oncology targeted therapy
SpringWorks Therapeutics is a commercial biopharmaceutical company focused on acquiring, developing, and commercializing targeted cancer therapies. This chart reflects average revenue expectations in the oncology sector. It provides an insight into the market's perception of the potential of SpringWorks' pipeline.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-targeted-therapy&v=1772513457395 "Future (projected) P/S market segment graph - Oncology targeted therapy")
Future (projected) P/S of the market as a whole
SpringWorks Therapeutics is a biopharmaceutical company specializing in the development of targeted therapies for the treatment of rare cancers and tumors. This chart reflects overall investor sentiment. The company's success in developing drugs for patients with limited treatment options fuels hopes for advances in personalized oncology.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513457418 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales SpringWorks Therapeutics
This chart illustrates the sales of SpringWorks Therapeutics, a biopharmaceutical company specializing in drugs for the treatment of rare tumors and cancers. Its revenue is generated from sales of already approved drugs. The trend shows how successfully the company is commercializing its targeted therapies.
Sales of companies in the market segment - Oncology targeted therapy
SpringWorks Therapeutics is a biopharmaceutical company specializing in the development of precision oncology drugs for patients with rare tumors and genetically defined cancers. This chart reflects the growth of the targeted therapy market. The company occupies an important niche, developing drugs for patient groups who previously had no effective treatment options.
Overall market sales
SpringWorks Therapeutics is a biopharmaceutical company specializing in the treatment of rare oncological diseases. Its market capitalization depends on the results of clinical trials. The overall economic situation, reflected in this chart, influences investor willingness to finance risky biotech projects.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company SpringWorks Therapeutics
SpringWorks Therapeutics is a biopharmaceutical company specializing in the development of targeted therapies for the treatment of rare cancers and tumors. Future revenue depends on the success of its drugs. The chart shows analysts' expectations for the sales of its oncology drugs.
%20sales%20of%20the%20company%20SpringWorks%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-SpringWorks-Therapeutics&v=1772513457535 "Schedule of future (projected) sales of the company SpringWorks Therapeutics")
Future (projected) sales of companies in the market segment - Oncology targeted therapy
SpringWorks Therapeutics is a biopharmaceutical company specializing in the development of targeted drugs for the treatment of rare cancers and tumors with specific genetic mutations. This chart shows the forecast for the entire oncology market, where precision medicine, the focus of SpringWorks, is one of the most promising areas.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-targeted-therapy&v=1772513457557 "Schedule of future (projected) sales of companies in the market segment - Oncology targeted therapy")
Future (projected) sales of the market as a whole
SpringWorks Therapeutics is a commercial biopharmaceutical company specializing in the development of targeted therapies for rare cancers and tumors. The company's success depends on the sales of its drugs and the results of its research. This graph, reflecting overall market sentiment, influences the company's valuation and its ability to fund further development.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513457628 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality SpringWorks Therapeutics
SpringWorks Therapeutics specializes in developing targeted therapies for rare cancers and tumors. While the company is in the commercialization stage of its first product, it still incurs significant R&D expenses. This chart shows its path to profitability, which depends on a successful drug launch and the development of its pipeline of new developments.
Market segment marginality - Oncology targeted therapy
SpringWorks Therapeutics is a commercial biopharmaceutical company specializing in the development of targeted therapies for the treatment of rare tumors and hematological malignancies. Profitability depends on the success of their approved drugs and progress in research. This chart shows the financial results of their activities at the forefront of precision oncology.
Market marginality as a whole
SpringWorks Therapeutics is a biopharmaceutical company focused on developing targeted therapies for rare cancers and genetically defined tumors. They often license promising molecules from larger companies. This overall profitability curve is irrelevant to them. Their success depends solely on the results of clinical trials.
Employees in the company, segment and market as a whole
Number of employees in the company SpringWorks Therapeutics
SpringWorks Therapeutics is a biopharmaceutical company specializing in rare cancers. As it moves closer to commercialization, its team is growing significantly through the hiring of sales professionals. This chart shows its transformation from an R&D company to a commercial one.
Share of the company's employees SpringWorks Therapeutics within the market segment - Oncology targeted therapy
SpringWorks Therapeutics is a biopharmaceutical company specializing in developing drugs to treat rare tumors and cancer. This chart reflects its rapid growth. It shows the size of its large and expanding team, which is preparing for the commercial launch of its lead drug and advancing one of the broadest pipelines in precision oncology.
Number of employees in the market segment - Oncology targeted therapy
SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing precision medicines for the treatment of rare oncological diseases. This chart shows the dynamics of employment in the oncology sector. The growth in sales and marketing personnel reflects the successful launch of the company's first drug and its transformation from an R&D startup.
Number of employees in the market as a whole
SpringWorks Therapeutics is a biotech company specializing in drugs for the treatment of rare cancers. Its success depends on the results of clinical trials and partnerships. A stable economic environment, reflected in this chart, is important for raising capital and for the future solvency of the healthcare system.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company SpringWorks Therapeutics (SWTX)
SpringWorks Therapeutics is a biotech company specializing in "precision oncology"—developing drugs for genetically defined patient groups. It's an R&D company. The chart shows that its market value reflects its scientific approach and drug portfolio. Its high market capitalization per employee reflects the value of its intellectual property.
%20of%20the%20company%20SpringWorks%20Therapeutics%20(SWTX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-SpringWorks-Therapeutics-SWTX&v=1772513457797 "Chart of market capitalization per employee (in thousands of dollars) of the company SpringWorks Therapeutics (SWTX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology targeted therapy
SpringWorks Therapeutics is a biopharmaceutical company specializing in the development of targeted therapies for the treatment of rare cancers and tumors. Its value is determined by the potential of its clinical programs. This chart demonstrates the high market valuation of its scientific assets and prospects based on its small team of scientists.
%20by%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-targeted-therapy&v=1772513457814 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology targeted therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
SpringWorks Therapeutics is a biopharmaceutical company focused on developing targeted therapies for rare cancers. The chart illustrates its valuation in niche oncology. The high market capitalization per employee reflects the significant potential of its drugs for patients with limited treatment options.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513457832 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company SpringWorks Therapeutics (SWTX)
SpringWorks Therapeutics is a biotech company that successfully commercialized Ogsiveo, a treatment for rare desmoid tumors. This represents a shift from R&D to commercialization. This chart illustrates this balance: profit per employee is the result of how Ogsiveo sales revenue compares to the costs of the rest of the R&D team.
%20Chart%20SpringWorks%20Therapeutics%20(SWTX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-SpringWorks-Therapeutics-SWTX&v=1772513457870 "Company Profit Per Employee (in thousands of dollars) Chart SpringWorks Therapeutics (SWTX)")
Profit per employee (in thousands of dollars) in the market segment - Oncology targeted therapy
SpringWorks Therapeutics is a commercial biopharmaceutical company focused on rare cancers and tumors. They already have an approved drug. This metric reflects the balance between revenue from sales of a high-margin orphan drug and continued high R&D expenditures.
%20in%20the%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-targeted-therapy&v=1772513457887 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology targeted therapy")
Profit per employee (in thousands of dollars) for the market as a whole
SpringWorks Therapeutics (SWTX) is a biopharmaceutical company specializing in targeted therapies for rare cancers. They have an approved drug (Ogsiveo). This chart is intended to show the transition from R&D losses to profitability. It reflects how successfully they are commercializing this niche drug.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513457893 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee SpringWorks Therapeutics (SWTX)
SpringWorks Therapeutics is a biopharmaceutical company focused on developing targeted therapies for the treatment of rare cancers and tumors. This chart reflects the commercial potential of its developments. Increasing revenue per employee will indicate successful drug launches and increased demand in oncology practices.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-SpringWorks-Therapeutics-SWTX&v=1772513457947 "Sales chart per company employee SpringWorks Therapeutics (SWTX)")
Sales per employee in the market segment - Oncology targeted therapy
SpringWorks Therapeutics (SWTX) is a biotech company specializing in precision oncology—developing drugs to treat cancers caused by specific genetic mutations. This chart shows how productive their R&D team is, measuring revenue (from partnerships or early sales) per scientist.
Sales per employee for the market as a whole
SpringWorks Therapeutics (SWTX) is a biopharmaceutical company specializing in rare oncology diseases. The company has an approved drug. This chart shows how successfully the company is moving from R&D to the commercial phase, generating revenue from sales of its niche but expensive drug.
Short shares by company, segment and market as a whole
Shares shorted by company SpringWorks Therapeutics (SWTX)
SpringWorks Therapeutics is a biotech company specializing in rare oncology diseases. It has one approved drug. The bearish sentiment shown by this chart may be related to bets on a slow commercial launch of its drug or the failure of its remaining clinical programs.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-SpringWorks-Therapeutics-SWTX&v=1772513458050 "Short Shares Chart for the Company SpringWorks Therapeutics (SWTX)")
Shares shorted by market segment - Oncology targeted therapy
SpringWorks Therapeutics (SWTX) is a biotech company developing targeted therapies for oncology and rare diseases. This is an area of high risk and potential breakthroughs. This chart reflects the collective skepticism of investors toward the entire biotech sector. A rising indicator indicates the market is skeptical of the success of clinical trials or the valuation of the entire industry.
Shares shorted by the overall market
SpringWorks is a clinical-stage biotech developing drugs for rare tumors. This chart illustrates the overall market pessimism. When fear reigns, investors are reluctant to finance a cash burn. They sell off shares of pre-profitable companies like SWTX, fearing they won't have enough capital to complete R&D in a market panic.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator SpringWorks Therapeutics (SWTX)
SpringWorks Therapeutics (SWTX) specializes in precision oncology, developing targeted drugs to treat rare tumors and cancers with specific mutations. This chart measures price momentum. It helps identify when investor enthusiasm (above 70) for trial data or disappointment (below 30) peaks.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-SpringWorks-Therapeutics-SWTX&v=1772513458123 "RSI 14 indicator chart for the company's stock SpringWorks Therapeutics (SWTX)")
RSI 14 Market Segment - Oncology targeted therapy
SpringWorks is a biotech company, a rare cancer hunter. Their specialty is targeted therapy (MEK and RAF inhibitors) for genetically specific tumors. The RSI_14_Seg index for "Oncology targeted therapy" (biotech) is driven by news. It shows the "temperature" of the entire segment. It helps us understand: is SWTX's growth due to their R&D, or is the entire biotech industry "overheated"?
RSI 14 for the overall market
SpringWorks (SWTX) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an easy way to raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast SWTX (SpringWorks Therapeutics)
SpringWorks Therapeutics is an oncology company specializing in precision medicine for the treatment of rare tumors and blood cancers. This chart shows the analysts' average 12-month forecast. It reflects their assessment of the commercial success of already approved drugs and the potential of the company's R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-SWTX-SpringWorks-Therapeutics&v=1772513458241 "A chart showing analyst consensus forecasts for the expected stock price. SWTX (SpringWorks Therapeutics)")
The difference between the consensus estimate and the actual stock price SWTX (SpringWorks Therapeutics)
SpringWorks (SWTX) is a precision oncology biotechnology company focused on developing targeted therapies for rare cancers and tumors. This chart shows the difference between the market valuation and the consensus forecast. It reflects how confident experts are in their R&D pipeline and the commercial launch of their drugs.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-SWTX-SpringWorks-Therapeutics&v=1772513458256 "A chart showing the difference between the consensus forecast and the actual stock price. SWTX (SpringWorks Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Oncology targeted therapy
SpringWorks Therapeutics is a biotech company specializing in precision oncology (targeted therapy) for the treatment of rare cancers and tumors. This chart shows general expectations for the targeted oncology sector. It reflects whether experts believe R&D investments in this niche will be successful.
Analysts' consensus forecast for the overall market share price
SpringWorks Therapeutics (SWTX) is a cancer sniper. It's a biotech company focused on targeted therapies—developing drugs to treat rare tumors and cancers with specific mutations. This chart shows the overall risk appetite, reflecting the market's willingness to fund breakthrough but high-risk R&D projects.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index SpringWorks Therapeutics
SpringWorks Therapeutics is a biopharmaceutical company specializing in targeted therapies for rare oncologies. Their model is "precision medicine." This chart is an integrated index reflecting the market's assessment of their scientific approach, clinical trial progress, and the commercial potential of their highly targeted drug candidates.
AKIMA Market Segment Index - Oncology targeted therapy
SpringWorks (SWTX) is an oncology company with a targeted approach. They specialize in developing drugs for rare tumors and cancers with distinct genetic mutations. This chart compares their composite index to the oncology sector average.
The AKIM Index for the overall market
SpringWorks Therapeutics is a biopharmaceutical company specializing in rare tumors and genetically defined cancers (Ogsiveo). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this successful commercial oncology company compares to overall economic trends.
